2017•The Lancet HIVRequires access

Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study

Catherine Orrell, Debbie P. Hagins, Elena Belonosova, Norma Porteiro, Sharon Lynn Walmsley, Vicenç Falcó, Choy Y. Man, Alicia Aylott, Ann M. Buchanan, Brian Wynne, Cindy Vavro, Michael Aboud, Kimberly Y. Smith, Pedro Enrique Cahn, Lidia Isabel Cassetti, Norma Porteiro Barreira, Jonathan Benjamin Angel, Alexandra de Pokomandy, Marianne Harris, Anita Rachlis, Sharon Lynn Walmsley, Clotilde Allavena, Oliver Bouchaud, Caroline Gatey, Agathe Rami, Salvatore Casari, Giovanni Di Perri, Adriano Lazzarin, Franco Maggiolo, Giovanni Penco, Tiziana Quirino, Giuliano Rizzardini, Jaime Federico Andrade-Villanueva, Juan Gerardo Sierra-Madero, Teresa L. Branco, Rosário Serrão, Eugénio Teófilo, Ivan Melendez-Rivera, Lizette Santiago, Carmen Zorrilla, Elena Belonosova, Oksana E. Chernova, Vadim Valentinovich Pokrovsky, Aza Gasanovna Rakhmanova, Olga Aleksandrovna Tsybakova, Eugene Voronin, Catherine Orrell, Tasneem Vally, Livhuwani ML. Farisani, Boitumelo Lucrecia Sebopa, Carlos Aguado Barros, Alfredo Cano Sánchez, Manuel Angel Castaño, Vicens Falcó Ferrer, Juan González‐García, José Hernández‐Quero, Eugenia Negredo Puigmal, Marı́a Jesús Pérez-Elı́as, Daniel Podzamczer Palter, Joaquín Portilla, Pompeyo Viciana Fernández, Weerawat Manosuthi, Kiat Ruxrungtham, David Harold Dockrell, Phillip Hay, Margaret Johnson, Nicola Mackie, Chloe M. Orkin, Steve Taylor, Laveeza Bhatti, Indira Brar, Robert Owen Brennan, Jerry L. Cade, Beata Casańas, Kathleen B. Casey, Douglas Cunningham, Edwin DeJesus, Craig Dietz, Robin Henry Dretler, Joseph J. Eron, Franco Felizarta, Kenneth H. Fife, Debbie P. Hagins, Margaret Hoffman-Terry, Mamta K. Jain, Marc Alexander Johnson, Clifford A. Kinder, Princy N. Kumar, Stanley T. Lewis, Cheryl McDonald, Armando D. Meza, Karam Mounzer, Cheryl L. Newman, Olayemi O. Osiyemi, Ronald Poblete, Rachel M. Presti, Moti N. Ramgopal, Joel Rosenstock, Rafik Samuel, Uriel Sandkovsky, Alyssa So Young Shon, Daniel J. Skiest, Louis M. Sloan, Catherine Butkus Small, Pablo Tebas, Cornelius N. Van Dam

Open publisher page 118 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 118 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Dolutegravir, Emtricitabine, Medicine, Abacavir, Atazanavir, Ritonavir, Lamivudine, Raltegravir

Related papers

Back to paper searchBrowse research topicsOriginal source
Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study — Research Paper | ScholarLens